Position: CEO and President since 2021. Employed since 2021.

Education: BSc in business administration and economics from Örebro University.

Experience: Former experience in the pharmaceutical industry includes CEO at Sedana Medical Group (2017-2021) and CEO at Unimedic Group (2010-2016), CEO at Eisai AB (2005-2010) and additional 10 years of experience in leading positions in sales and marketing at AstraZeneca (including launch of Nexium), Meda and Wyeth.

Other current assignments: Member of the Board of FrostPharma AB and FrostPharma Holding AB. Deputy CEO and deputy Member of the Board of Waxholm by the sea AB.

Holdings in Cinclus Pharma: Ordinary shares: 104,400 (own), Share rights (PSP2024): min 11,600 max 104,400, ESOP 24/27: 200,000, QESO: 22/25: 700 (conv. Term 1:80), QESO: 24/27: 7,391.

Position: CFO since 2021. Employed since 2021.

Education: BSc in Business Administration and Economics from Stockholm University.

Experience: Former CFO of Sedana Medical Group (2017-2021) and Managing Director at Cross Pharma AB (2015-2016). Maria has also extensive experience from leading positions within finance for the past 25 years within Medivir, Biovitrum, Bristol Myers Squibb and Ericsson.

Other current assignments: Member of the Board of FAYSIT – Finance At Your Service In Tyresö AB.

Holdings in Cinclus Pharma: Ordinary shares: 11,400 (own and via related parties), Share rights (PSP2024): min 5,375 max 26,875, QESO: 22/25: 700 (conv. term 1:80), QESO: 24/27: 7,391.

Position: CMO since 2022. Employed since 2022.

Education: MD and Ph.D in Medical Sciences from Karolinska Institutet.

Experience: Consultant in internal medicine and hematology/hematooncology with more than 15 years’ of clinical experience. From 2009 full time in the pharmaceutical industry at different positions within medical affairs and clinical development at national, regional and global levels in Genzyme, Roche, Alexion, Alnylam and Oncopeptides.

Holdings in Cinclus Pharma: Ordinary shares: 3 325 (own), Share rights (PSP2024): min 3,325 max 16,625, QESO: 22/25: 700 (conv. term 1:80), QESO: 24/27: 7,391, Warrants 21/24: 1,450 (conv. term 1:80).

Position: Commercial Director since 2022, consultant since 2022.

Education: BSc, Biochemistry, Molecular Biology, Microbiology from Sydney University and Master Commerce, Marketing and Finance from University of NSW.

Experience: Extensive experience from the pharmaceutical industry. Former Head of Digital Transformation at Novartis and Ass. Global Brand Director of Diabetes at Novartis. Several executive positions within AstraZeneca such as VP Nexium, Global Marketing and Development, Global Product Director and Marketing Director Gastroenterology for Nexium and Losec.

Other current assignments: Member of the Board of PCW Consulting AB. Deputy Member of the Board of Wallich Composite AB and Wallich Holding AB.

Holdings in Cinclus Pharma: -

Position: Executive R&D Director since 2024. Consultant since 2024.

Education: PhD, Prof. in Molecular Genetics.

Experience: Senior manager with 20+ years of experience in R&D of novel pharmaceuticals overseeing cross-functional teams. Held leadership roles in publicly traded biopharmaceutical companies and privately owned biotech firms. Managed R&D portfolios across diverse therapeutic areas with an emphasis on clinical and product development, regulatory affairs, and vendor management.

Other current assignments: Prof. in Molecular Genetics, University of Gothenburg, Member of the Board in Sixera Pharma.

Holdings in Cinclus Pharma: -

Position: Director of Corporate and Business Development since 2023. Consultant since 2023.

Education: BS Biology, St Mary's College of CA, MBA Harvard Business School.

Experience: 30 years experience in Biopharma industry. Jesper has served as Head of Business and Corporate Development at both Evotec and SOBI. CEO at Biopharma companies Index Pharmaceuticals and Klaria Pharma. Jesper also worked as a Private Equity investor while he was Managing Director, Europe at New York based Life Science focused investment fund Oberland Capital.

Holdings in Cinclus Pharma: Ordinary shares: 42 890 (via related party).